GlassScriptPhysician profile
Karen Guidry
NPI 1346864725
$3,346.50
in general payments reported to CMS, 2019-2025
33 companies · $635 in 2025
The $635 reported for 2025 was more than what 79% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $247 · 2022: $602 · 2023: $989 · 2024: $873 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,485 · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,485.12 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $479.76 | 2023-2025 | |
| Novo Nordisk INC | $314.93 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $305.88 | 2023-2025 | Mounjaro, Trulicity, Jardiance |
| Novartis Pharmaceuticals Corporation | $251.27 | 2021-2024 | |
| Amgen INC. | $223.30 | 2021-2025 | Repatha, Otezla, Repatha |
| Actelion Pharmaceuticals US, INC. | $220.17 | 2021-2025 | Uptravi, Opsumit |
| Glaxosmithkline, LLC. | $159.08 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $146.56 | 2022-2025 | Breztri, Farxiga, Fasenra |
| Pfizer INC. | $122.08 | 2022-2024 | |
| Xeris Pharmaceuticals, INC. | $111.23 | 2023-2024 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $100.27 | 2021-2023 | Belsomra, Steglatro, Januvia |
| Shield Therapeutics INC | $93.93 | 2024-2025 | |
| Exact Sciences Corporation | $80.70 | 2023-2025 | Cologuard Collection Kit |
| Viiv Healthcare Company | $79.32 | 2025 | Apretude |
| Dexcom, INC. | $74.31 | 2023 | Dexcom G6 Transmitter |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.84 | 2022-2025 | Ofev, Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $70.18 | 2022 | |
| Sumitomo Pharma America, INC. | $52.29 | 2025 | Gemtesa |
| Astellas Pharma US INC | $46.37 | 2024 | Veozah |
| Inspire Medical Systems, INC. | $42.62 | 2024 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $37.60 | 2022 | |
| Gilead Sciences, INC. | $36.61 | 2025 | |
| Abiomed | $28.34 | 2022 | |
| Corcept Therapeutics | $24.62 | 2025 | Korlym |
| Kyowa Kirin, INC. | $23.66 | 2025 | |
| Esperion Therapeutics, INC. | $23.34 | 2024 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $22.78 | 2024 | |
| Janssen Pharmaceuticals, INC | $21.13 | 2022 | |
| Vanda Pharmaceuticals INC. | $20.65 | 2023 | Hetlioz |
| Phathom Pharmaceuticals, INC. | $19.25 | 2025 | Voquezna |
| Phadia US INC. | $15.75 | 2024 | Immunocap |
| Otsuka America Pharmaceutical, INC. | $14.32 | 2025 | Rexulti |
| Horizon Therapeutics Plc | $13.36 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Guidry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.